{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-033411","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2022-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.772763+00:00","generated_at":"2026-06-23T09:31:30.389847+00:00","sec_items":["2.01","3.03","5.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lisata Therapeutics formed via Caladrius-Cend merger; ~$76M cash, ticker LSTA","bullets":["Merger closed 9/15/22: Caladrius issued 0.5338 shares per Cend share after 1:15 reverse split; post-merger shares ~7.82M.","Former Caladrius stockholders own ~52%, former Cend stockholders ~48% of combined company.","Combined cash and investments ~$76M; focus on CendR Platform oncology pipeline and existing programs.","Name changed to Lisata Therapeutics; ticker LSTA on Nasdaq; former ticker CLBS discontinued.","Board expanded with four Cend designees; David Slack named President & CBO; leadership team includes CEO David Mazzo."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-033411","json":"https://secwatch.observer/filing/0001140361-22-033411.json","markdown":"https://secwatch.observer/filing/0001140361-22-033411.md","text":"https://secwatch.observer/filing/0001140361-22-033411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/brhc10041800_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:31:30.389847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4592383e9e","claim":"Anne C. Whitaker resigned as Director at LISATA THERAPEUTICS, INC..","evidence_excerpt":"Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"47dac8d4e1","claim":"Michael H. Davidson resigned as Director at LISATA THERAPEUTICS, INC..","evidence_excerpt":"Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"81d6b7bd2f","claim":"Peter G. Traber resigned as Director at LISATA THERAPEUTICS, INC..","evidence_excerpt":"Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cd42c51bb5","claim":"Steven S. Myers resigned as Director at LISATA THERAPEUTICS, INC..","evidence_excerpt":"Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f1bd331db4","claim":"David Slack was appointed as President and Chief Business Officer at LISATA THERAPEUTICS, INC..","evidence_excerpt":"appointed David Slack as a member of the Company’s board of directors and as the Company’s President and Chief Business Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}